Unlock Editor’s Digest for free
FT editor Roula Khalaf selects her favorite stories in this weekly newsletter.
The spigots are at least partially open. From European beauty to American social technology to Chinese bubble tea, some 370 initial public offerings have raised about $32.3 billion in the first four months of the year.
London is conspicuous by its virtual absence (371 million insignificant dollars).
British runners, an inherently glass-half-full bunch, are unfazed. Peel Hunt, who coined his own IPO speedometer tracker, sees “more positive” early indicators after a miserable 2023. Boost your confidence: Increase European IPOs and encourage broader activity in equity capital markets.
Investors will hope they are right. More than national pride is at stake when IPOs generate juicy returns from day one. Shares of a European private equity firm CVC appeared up 25 percent when they debuted in Amsterdam last week. Shares of Astera Labs, which began trading on Nasdaq in March, gained 72 percent.
UK veterans will know the procedure. Buying early and reselling was a basic strategy for the stock glut unleashed by then-Prime Minister Margaret Thatcher’s privatization drive in the 1980s and 1990s. That galvanized desired retail participation, but short-term investors are no record. of healthy shareholders.
Several factors fuel these outbreaks. One is the IPO discount, typically a roughly 20 percent cut to peer valuations. Underwriters, fearful of being stuck with stocks, have a natural tendency to leave money on the table.
But issuers are also becoming more restrained on pricing: unmet demand represented by bloated order books supports stocks. This is especially useful for those who may be considering stocks as an acquisition currency in the future.
Still, there are many failures. German perfume and cosmetics retailer Douglas fell on its debut last month. Last year, more than half of US IPOs registered on the first day. according to data compiled by Jay Ritter of the University of Florida. First day earnings in the US fluctuate wildlyeven when aggregated into averages: from a meager 7 percent in the 1980s to 65 percent during the dotcom bubble years of 1999-2000.
Diversification is a solution. IPO ETFs offer just that: tracking theand IPOX benchmarks that invest in IPOs, direct listings, and companies that have acquired others within their first seven years of trading.
Tracking these indices would have paid off in one and five years, but (and unlike the S&P 500 or the Euro Stoxx 50) money was lost in three years.
The top 10 holdings in the First Trust IPOX Europe Equity Opportunities ETF, which is UCITS compliant so available to UK investors, include Arm (because it is based in the UK, even if listed in the US) and GSK. The UK-listed drugmaker bought oncology-focused Tesaro in 2019 and Sierra Oncology in 2022, which listed in 2012 and 2015, respectively.
The comparable US fund includes transportation app Uber and accommodation site Airbnb.
An alternative (and riskier) route is through pre-IPO candidates, or rather potential IPOs. This can be done through UK listed investment trusts such as Chrysalis Investments and Augmentum Fintech.
The former’s holdings include fintechs Klarna and Starling Bank, both IPO candidates, as well as chip and online travel makers. Shares in Chrysalis, which has a market capitalization of less than £500m, rose about 40 per cent last year.
There are certainly risks here. But the dearth of IPOs in the country does not mean that British investors with the stomach for it are excluded from the party.